2024
Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia
Garcia C, Lyons K, Liu T, Iacobucci I, Novak A, Argabright A, Donnelly A, Grandvallet Contreras J, Geng H, Smith S, Zhou X, Müschen M, Dick J, Haines J, D'Alessandro A, Mullighan C, Phang T, Kohler M, Witkowski M. Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood 2024, 144: 1446-1446. DOI: 10.1182/blood-2024-201015.Peer-Reviewed Original ResearchB-cell acute lymphoblastic leukemiaB-ALL cell linesCAR-TCAR-T therapyB-ALL cellsAcute lymphoblastic leukemiaHuman B-ALL cell linesTP53-MUTLoss-of-function mutationsTP53 mutationsLymphoblastic leukemiaCD19-directed chimeric antigen receptor T cellsB-ALL diagnosisRelapsed B-ALLRelapsed B-cell acute lymphoblastic leukemiaRelapsed/refractory B-cell acute lymphoblastic leukemiaFree fatty acid transportB cell acute lymphoblastic leukemia cellsChimeric antigen receptor T cellsCD19 CAR-T therapyHigh-risk genetic featuresCAR-T cell therapyAssociated with chemotherapy resistanceResistant to conventional chemotherapyPediatric B-ALL patients
2018
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
Uy N, Nadeau M, Stahl M, Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. Journal Of Blood Medicine 2018, 9: 67-74. PMID: 29713210, PMCID: PMC5908210, DOI: 10.2147/jbm.s136575.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChemotherapy-based approachesInotuzumab ozogamicinAcute lymphoblastic leukemiaB-ALLLymphoblastic leukemiaChimeric antigen receptor (CAR) T-cell productBispecific T-cell engager blinatumomabAcute B-cell lymphoblastic leukemiaPhiladelphia chromosome-positive diseaseSecond-line salvage therapyB-cell lymphoblastic leukemiaExcellent clinical activityT-cell productsRelapsed B-ALLCD22 monoclonal antibodySalvage therapyAdult patientsSupportive careCell transplantationLeukemic blastsSuperior survivalClinical trialsClinical activityOzogamicinClinical data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply